What if Resverlogix were to market apabetalone for reducing cardiovascular disease in FA patients, who have an increased risk of CVD? As long as they don't claim that the benefits aren't due to increased frataxin, then there might not be a patent conflict with Pfizer. Apabetalone and other Resverlogix BET inhibitors are covered under patents to treat inflammatory diseases and CVD. Since FA has inflammatory/NFkB and CVD components, then there may be a work around. Furthermore, the Pfizer patent showed only a modest effect of apabetalone  to modulate frataxin so there may be more clinical benefits for FA patients from the anti-inflammatory and cardioprotective aspects of apabetalone than its frataxin modulating effects. 

BearDownAZ